Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 12/20 | 0.54 |
| ▸ | BRAF | P15056 | 11/20 | 0.54 |
| ▸ | RAF1 | P04049 | 10/20 | 0.54 |
| ▸ | DDR2 | Q16832 | 6/20 | 0.54 |
| ▸ | DDR1 | Q08345 | 5/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | ARAF | P10398 | 1/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | TEK | Q02763 | 1/20 | 0.47 |
| ▸ | MELK | Q14680 | 1/20 | 0.47 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19073445 | 0.88 | CSF1R (0.52) | CSF1RBRAFRAF1DDR2DDR1 | |
| SCHEMBL2233027 | 0.88 | BRAF (0.55) | CSF1RBRAFRAF1DDR2DDR1 | |
| SCHEMBL2310549 | 0.87 | BRAF (0.50) | CSF1RBRAFRAF1DDR2DDR1 | |
| SCHEMBL2237093 | 0.86 | ERN1 (0.54) | CSF1RBRAFRAF1DDR2DDR1 | |
| SCHEMBL19057084 | 0.86 | CSF1R (0.47) | CSF1RBRAFRAF1DDR2DDR1 | |
| SCHEMBL2314140 | 0.85 | CSF1R (0.52) | CSF1RBRAFRAF1DDR2DDR1 | |
| SCHEMBL14137176 | 0.84 | CSF1R (0.51) | CSF1RBRAFRAF1DDR2DDR1 | |
| SCHEMBL2310790 | 0.84 | BRAF (0.55) | CSF1RBRAFRAF1DDR2DDR1 | |
| SCHEMBL2315583 | 0.83 | BRAF (0.46) | BRAFL3MBTL1 | |
| SCHEMBL19072914 | 0.83 | CSF1R (0.50) | CSF1RBRAFRAF1DDR2DDR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2528925-B1 | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES | HANMI SCIENCE CO LTD (KR) | 2017-07-05 | — | — | EP | disclosed |
| EP-2528925-B1 | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES | HANMI SCIENCE CO LTD (KR) | 2017-07-05 | — | — | EP | disclosed |
| US-8999973-B2 | Thieno[3,2-d]pyrimidine derivatives having inhibitory activity on protein kinases | HANMI SCIENCE CO., LTD (KR) | 2015-04-07 | — | — | US | disclosed |
| US-8999973-B2 | Thieno[3,2-d]pyrimidine derivatives having inhibitory activity on protein kinases | HANMI SCIENCE CO., LTD (KR) | 2015-04-07 | — | — | US | disclosed |
| US-8999973-B2 | Thieno[3,2-d]pyrimidine derivatives having inhibitory activity on protein kinases | HANMI SCIENCE CO., LTD (KR) | 2015-04-07 | — | — | US | disclosed |
| US-20130053370-A1 | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES | HANMI SCIENCE CO., LTD. (KR) | 2013-02-28 | — | — | US | disclosed |
| US-20130053370-A1 | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES | HANMI SCIENCE CO., LTD. (KR) | 2013-02-28 | — | — | US | disclosed |
| US-20130053370-A1 | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES | HANMI SCIENCE CO., LTD. (KR) | 2013-02-28 | — | — | US | disclosed |
| EP-2528925-A2 | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES | Hanmi Science Co., Ltd. (KR) | 2012-12-05 | — | — | EP | disclosed |
| WO-2011093684-A2 | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES | HANMI HOLDINGS CO., LTD. (KR) | 2011-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053370-A1 | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES | CDK2, TK1, DTYMK | CSF1R 3387/4885BRAF 60/4885RAF1 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.